

200 new therapies and means to diagnose most rare diseases by the year 2020



Co-operation at international level to stimulate, better coordinate & maximise output of rare disease research efforts around the world



34 committed members

Europe

E-RARE Consortium (EU)

European Commission (EU)

EURORDIS (EU)

French Association against Myopathies (FR)

French National Research Agency (FR)

German Federal Ministry of Education and research (DE)

Italian Higher Institute of Health Research (IT)

Italian Telethon Foundation (IT)

Lysogene (FR)

Netherlands Organisation for Health Research and Development

Prosensa (NL)

Spanish Carlos III Health Institute (ES)

UK National Institute for Health Research (UK)



<u>Asia</u>

BGI (CN)

Korea National Institute of Health (KR)

Australia

National Health and Medical Research Council

Western Australian Department of Health

North America

Canadian Institutes for Health Research (CA)

FDA Orphan Products Grants Program (US)

Genome Canada (CA)

Genetic Alliance (US)

Mendelian Disorders Genome Centres (US)

National Centre for Translational Sciences (US)

National Cancer Institute (US)

National Institute of Neurological Disorders and Stroke (US)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)

National Institute of Child Health and Human Development (US)

National Eye Institute (US)

NKT Therapeutics (US)

NORD (US)

Office of Rare Diseases (US)

PTC Therapeutics (US)

Sanford Research (US)

Shire (US)



International cooperation: Working on the big challenges

NEW: Global Research Collaboration for Infectious Disease Preparedness

International K.O. Mouse Consortium

International Cancer Genomics Consortium



International Rare Disease Research Consortium

International Initiative for Traumatic Brain Injury Research

International Human Epigenome Consortium

International Human Microbiome Consortium

NEW: Global Alliance for

Chronic Diseases



'Programme-level co-operation': how does it work?



Identify common strategic goals

Agree to share tasks (and costs)

Issuing of calls in the cooperating country(ies)

Independent evaluation, selection and funding of projects

Funded projects work closely together

Results, data and standards are being shared



Overview of EU research funding 25 September 2013

HORIZ N 2020

Irene Norstedt Head of Personalised Medicine Unit Health Research Directorate DG Research & Innovation



R&I in Horizon 2020 (2014-2020)

DISCLAIMER: Pending formal adoption by the EU of the Horizon 2020 legal texts, the content of these slides is not definitive and so should not be taken as such, nor used or referred to as such in any way or for any purpose

Research and Innovation



Fhe European Union:500 million people – 28 countries





Concept



all EU countries



pulling resources



into one R&I programme





Europe 2020 – Europe's growth strategy

• Smart growth

Better education, more research, greater use of communication technologies

• Sustainable growth

A resource - efficient, greener and more competitive economy

• Inclusive growth

More and better jobs, investment in skills and training, modernisation of the labour market and welfare systems, spreading the benefits of growth to all parts of the EU

• Good economic governance

Better coordination of economic policy





Europe 2020 - 5 EU headline targets

- 75% employment rate (% of population aged 20-64 years)
- 3% investment in R&D (% of EU's GDP)
- "20/20/20" climate/energy targets
- School drop-out rates lower than 10% and at least 40% of the population aged 30-34 having completed tertiary education;
- Reducing those at risk of poverty or exclusion by at least 20 million





Investment in R&D is part of the solution to exit from the economic crises





30 years of EU funded R&I







Three priorities:

- **1. Excellent science**
- 2. Industrial leadership
- 3. Societal challenges





- World class science is the foundation of tomorrow's technologies, jobs and wellbeing
- Europe needs to develop, attract and retain research talent
- Researchers need access to the best infrastructures





Priority 1: Excellent science What:

European Research Council

Frontier research by the best individual teams

Future and Emerging Technologies

Collaborative research to open new fields of innovation

Marie Curie actions

Opportunities for training and career development

Research infrastructures (including e-infrastructure) Ensuring access to world-class facilities





- Strategic investments in key technologies (e.g. advanced manufacturing, microelectronics) underpin innovation across existing and emerging sectors
- Europe needs to attract more private investment in research and innovation
- Europe needs more innovative SMEs to create growth and jobs





Priority 2 Industrial Leadership What:

Leadership in enabling and industrial technologies (ICT, nanotechnologies, materials, biotechnology, manufacturing, space)

Access to risk finance

Leveraging private finance and venture capital for research and innovation

Innovation in SMEs

Fostering all forms of innovation in all types of SMEs





- Concerns of citizens and society/EU policy objectives (climate, environment, energy, transport etc) cannot be achieved without innovation
- Breakthrough solutions come from multidisciplinary collaborations, including social sciences & humanities
- Promising solutions need to be tested, demonstrated and scaled up





Priority 3 Societal challenges What:

Health, demographic change and wellbeing

Food security, sustainable agriculture, marine and maritime research & the bioeconomy

Secure, clean and efficient energy*

Smart, green and integrated transport

Climate action, resource efficiency and raw materials

Inclusive, innovative and secure societies





- Collaborative research projects require at least three legal entities from different EU Member States
- Activities requiring at least one legal entity
 - European Research Council
 - Training & mobility action
 - SME instrument
 - Coordination & support actions
- Calls for proposals open to organizations from countries outside Member States and Associated Countries





Partnerships

Innovation Investment Package

10 Public-public partnerships and Public-private partnerships presented -10 July 2013- proposed EU contribution 22 Billion Euro

Innovative Medicines Initiative 2, Clean Sky 2, Fuel Cells and Hydrogen 2, Bio-based Industries, Electronics (ECSEL), SESAR (European Air Traffic Management System), European and Developing Countries Clinical Trials Partnership (EDCTP2), The European Metrology Programme for Research and Innovation (EMPIR), Eurostars 2 (to stimulate growth and job creation by supporting innovative SMEs), Active and Assisted Living Research and Development Programme





Marie Skłodowska-Curie Actions (MSCA)





Marie Curie Actions - Research Fellowship Programme

Marie Curie Fellowships are European research grants available to researchers regardless of their nationality or field of research. In addition to generous research funding scientists have the possibility to gain experience abroad and in the private sector, and to complete their training with competences or disciplines useful for their careers. Read more about various funding schemes and requirements for applying.



م





www.ec.europa.eu/research/mariecurieactions

AND Y



Training Actions

Innovative Training Networks	ITN	Support for doctoral and early-stage training Training Networks, European Industrial Doctorates, European Joint Doctorates
Individual Fellowships	IF	Support for experienced researchers undertaking international and inter-sector mobility: European Fellowships and Global Fellowships Dedicated support for career restart and reintegration
Research and Innovation Staff Exchange	RISE	International and inter-sector cooperation through the exchange of staff
Co-funding of programmes	COFUND	Co-funding of regional, national and international programmes: - doctoral programmes - fellowship programmes



What is ERC?

The ERC supports excellence in frontier research through a bottom-up, individual-based, pan-European competition





ERC - 25 panels for all areas of science

Physical	Mathematics	Social Sciences & Humanities		
Sciences &	Fundamental constituents of matter Condensed matter physics	6 panels		
Engineering	Physical and analytical chemical science	esdividuals, institutions and marke		
	Synthetic chemistry and materials	Institutions, values, beliefs and		
10 panels	Computer science and information			
	Systems and communication engineering	ignvironment, space and populatio		
	Products and processes engineering	The Human Mind		
	Universe sciences	Cultures and cultural production		
	Earth system science	The study of the human past		
Life	Molecular and structural biology and bio	chemistry		
Sciences	Genetics, genomics, bioinformatics and systems biology			
	Cellular and developmental biology			
9 panels	Physiology, pathophysiology and endocrinology			
	Neurosciences and neural disorders			
	Immunity and infection			
	Diagnostic tools, therapies and public health			
	Evolutionary, population and environmental biology			
	Applied life sciences and biotechnology			





EU-funded Health Research

Iiro Eerola Scientific Project Officer Unit for Personalised Medicine Directorate for Health Research DG Research & Innovation European Commission





The FP7 Health Programme

The largest multi-national fund

- for collaborative research, global consortia, and public-private co-operation
- to fund excellent applied health research and innovation
- to bring together leading players from Europe and across the globe
- to tackle key European and global health challenges





State of play

Key figures

6 b€ invested to date

1,000 projects

11,000 teams

3,500 organisations

130 countries

First outcomes (on 281 closed projects)

200 patent applications

9,000 publications

3,3 average SJR* publication

30 spin-offs created





EU health research delivers results for patients

- Treat OA better treatment
 & diagnosis of osteoarthritis
- EU contribution: €11.9 million
- Helped develop TIGENIX' lead product ChondroCelect© for cartilage regeneration in the knee
- This product is the first ATMP (Advanced Therapy Medicinal Product) approved in the EU.

www.treatoa.eu





EU health research concentrates scarce resources



- Alpha Man project is developing a promising treatment for patients suffering from the rare disease, alphamannosidosis.
- Alpha mannosidosis has a prevalence of 1 in 500.000 people
- A biotechnologically derived human enzyme has successfully completed a phase 2a clinical trial
- Three projects from 2001 to 2013 have led to this stage, with a total EU contribution of ~€10 million
- European research has been crucial given the low case numbers per member state and the limited incentive for private investment





EU level health research co-ordinates



- ...objectives which can only be achieved at European / global level
- e.g. the Blueprint project Europe's coordinated contribution to the International Human Epigenome Consortium
- Agreed goal of IHEC: generate 1000
 epigenomes
- SMEs are embedded in the consortium, paving the way for the next phase of research, drug development.



Duration: October 2011 - April 2016 Budget: EUR 39.9 million (EU contribution EUR 30 million)

Partners/countries

BLUEPRINT involves 41 partners from nine EU Member States, Switzerland and Israel. A full list is available at www.blueprint-epigenome.eu

Project website www.blueprint-epigenome.eu



IMI: Europe's highway to better medicines



- New type of public/private partnership
- 1:1 funding, joint decision making
- All EU funding goes to SMEs, academia, patient organisations and regulatory agencies
- Large pharmaceutical industry, represented by EFPIA, contributes in-kind

www.imi-europa.eu





Europe's highway to better medicines





In the pipeline: IMI2

- Commission proposal published in July
- Mission: create an even more powerful research and innovation machine – with broader objectives and a wider range of activities and partners
- Key objectives:
 - pave the way for the breakthrough vaccines, medicines and treatments which we will need in the near future
 - Enable top quality research and innovations with great public health benefits and commercial possibilities







European & Developing Countries Clinical Trials Partnership (EDCTP)

- A first in 'Joint Programming' between European national research programmes
- Test-bed to pioneer the coordination, joint implementation and integration of European national research programmes





www.edctp.org




EDCTP-funded clinical trials 2003-2011

HIV/AIDS 27 clinical trials	• Drugs • Vaccines • Microbicides	14 9 4
<u>Tuberculosis</u> 18 clinical trials	 Drugs Vaccines Diagnostics 	7 7 4
<u>Malaria</u> 12 clinical trials	• Drugs • Vaccines	10 2
Research & Innovation		



In the pipeline: EDCTP2

• EDCTP2 launch in early 2014 expected with:

a) Larger scope (including neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation)

- b) Bigger budget
- c) Longer duration
- 16 European countries have committed to spend almost €600 million on EDCTP2
- EU will provide matching co-funding through its Horizon 2020 programme







US organisations in FP7 Health



• **152 US participations:**

- 63 Universities
- 39 Research organisations
- 27 SMEs
- 13 Foundations
- 10 Other (International organisations, FDA etc.)

Receiving 51 million €





5 main US participating organisations





BESTCILIA: Better Experimental Screening and Treatment for PCD

- Primary Ciliary Dyskinesia (PCD) is a rare, genetically heterogeneous disorder causing severe, chronic destructive airway disease with progressive loss of lung function
- The main goal of the project is to characterise the clinical course and improve the diagnosis and treatment of PCD patients

Participants: DE, CH, CY, DK, EL, NL, PL, UK, US (University of Miami)

EU contribution: € 2.9 million

www.bestcilia.eu







IDEA: Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth infections: An African-European Research Initiative

 The primary objective of IDEA is to determine whether and how the presence of worm infections modulate immune responses specific to HIV, TB and Malaria, the clinical course of these diseases, and vaccination and vaccine-induced immune responses

Participants: 6 EU countries, 5 African countries and the US (Vaccine & Gene Therapy Institute Florida)

EU contribution € 10.3 million

www.idearesearch.eu







Health R&I in Horizon 2020 (2014-2020)





Health Challenge

Understanding health, wellbeing and disease

Preventing disease

Treating and managing disease

Active ageing and selfmanagement of health

Methods and data

Health care provision and integrated care

Unravelling the complexity of health and disease

[DRAFT]

Towards personalised, safe and more effective health interventions

Advancing active and healthy ageing

Improving health information, data exploitation and providing an evidence base for health policies and regulation

Integrated, sustainable, citizen centred care





How to participate in Horizon 2020





The basics (based on health programme)

- 1b€/year devoted to health research in Horizon 2020
- One rule: Minimum 3 partners from 3 EU countries + anyone else from anywhere in the world
- Project duration: 3-5 years
- Call publication: planned December 2013





Why should I go for EU funding?

- **1.** Build a strong network with top EU organisations and scientists
- 2. Share complementary knowledge & experience
- **3.** Receive funding for world-class research
- **4.** Get a first-hand experience with EU businesses and healthcare markets
- 5. Discover Europe: culture, art, food and wines ©!





How to apply?

- **1.** Read the call, identify a relevant topic
- **2. Find EU partners**
- **3.** Write and submit your proposal
- 4. Get funded (~10% success rate)!

http://ec.europa.eu/research/participants/portal





Find a partner for you project

- Get in touch with your national contact point: http://ec.europa.eu/research/participants/portal/page/nationalcontactpoint
- Fit for Health: http://www.fitforhealth.eu
- Health competence:
 http://www.healthcompetence.eu
- IMI partnering platform: http://www.imi-partnering.eu





We need your expertise

- Register as an expert
- ... or make sure that your profile is up to date

Join the database of independent experts for European research and innovation

The European Commission appoints independent experts to assist with research and innovation assignments including the evaluation of proposals, the review of projects and the monitoring of programmes or policies.



http://ec.europa.eu/research/participants/portal/page/welcomeexpert





Thank you!

Irene.Norstedt@ec.europa.eu Iiro.Eerola@ec.europa.eu

http://ec.europa.eu/research/health

